The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis.

ABSTRACT:

Background

Retinopathy of prematurity (ROP) is typically treated with laser photocoagulation and/or intravitreal anti-vascular endothelial growth factor (anti-VEGF). To the best of our knowledge, most systematic reviews have focused on comparing anti-VEGF against laser treatment while comparisons between different anti-VEGF agents are lacking. Thus, we conducted this meta-analysis to compare the efficacy and safety of different anti-VEGF agents or laser after primary ROP therapy.

Methods

We conducted a comprehensive search across multiple databases up to November 2022. We included studies that used anti-VEGF or laser for ROP with comparable cohorts.

Results

Overall, 44 studies were included in this meta-analysis. When comparing anti-VGEF with laser, we found that the

SUBMITTER: Chen J 

PROVIDER: S-EPMC10561404 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature